Fennec Pharmaceuticals

Historical price data

Fennec Pharmaceuticals is a commercial-stage biotech with a focused mission: to prevent cisplatin-induced hearing loss (CIO), a severe and permanent side effect affecting up to 90% of treated pediatric patients. Its sole asset, Pedmark (sodium thiosulfate injection), received FDA approval in September 2022, marking the first and only approved therapy for this indication. The company's strategy centers on the commercial rollout of Pedmark in the U.S., supported by lifecycle management through label expansion studies and strategic collaborations to drive adoption and address a significant unmet medical need.

Fennec's platform is based on the chemoprotectant sodium thiosulfate (STS), formulated and timed for post-cisplatin administration to selectively neutralize ototoxic platinum in the cochlea without interfering with anti-tumor efficacy.

Pedmark enjoys a first-mover advantage with no direct, approved competitors for preventing cisplatin-induced hearing loss. The main competition is the current standard of care (reactive audiological monitoring and hearing aids). Long-term threats include generic sodium thiosulfate (post-patent) and early-stage investigational otoprotectants, but Fennec's recent patent settlement provides a clear exclusivity runway.